Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Abstract Pevonedistat (TAK924) is a Nedd8-activating enzyme inhibitor with preclinical activity in non-Hodgkin lymphoma (NHL). This open-label, Phase I, multicenter, investigator-sponsored study enrolled patients with relapsed/refractory (R/R) NHL and chronic lymphocytic leukemia (CLL). The primary...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Pallawi Torka, Swetha Kambhampati Thiruvengadam, Lu Chen, Xiaoguang Wang, Canping Chen, Dan Vuong, Hanjun Qin, Alexandra Muir, Kirsten Orand, Ivana Borja, D. Lynne Smith, Alex F. Herrera, Stephen E. F. Spurgeon, Byung Park, Lionel D. Lewis, Francisco Hernandez-Ilizaliturri, Zheng Xia, Alexey V. Danilov
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Publishing Group 2023-01-01
Edice:	Blood Cancer Journal
On-line přístup:	https://doi.org/10.1038/s41408-022-00763-w
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!